Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXXON, INC (MXON.Nasdaq BB) Disposable syringe technology -- Ignore unavailable to you. Want to Upgrade?

To: campe who wrote (85)	7/14/1999 8:38:00 PM
From: bcjt	Respond to of 105

ragingbull.com bcjt

To: campe who wrote (85)	7/19/1999 11:20:00 AM
From: bcjt	Read Replies (1) \| Respond to of 105

Maxxon Gains Value With Ives' Clearance for Trading On Pink Sheets TULSA, Okla., Jul 19, 1999 (BUSINESS WIRE via COMTEX) -- Maxxon, Inc. (OTCBB: MXON) today announced that the Common Stock of Ives Health Company, Inc. ("Ives") has been cleared by the National Association of Securities Dealers (NASD) for trading on the Pink Sheets(R) under the symbol "IVEH." Ives markets and distributes 27 different homeopathic, weight loss, natural remedy and nutritional supplement products through major retail food and drug store chains. Maxxon owns 1,700,000 shares, or approximately 17%, of Ives Common Stock. Maxxon's shares are restricted until January, 2000. Ives markets its products in over 800 independent retail pharmacies and over 1,700 different chain pharmacy accounts. One of Ives' principal distribution alliances is with Winn-Dixie, which has more than 1,140 retail grocery stores located primarily in the Southeastern U.S., with 747 of those stores having pharmacies. Ives recently signed a distribution agreement with Winn-Dixie that will allow Ives products to be prominently featured in each of the 747 Winn-Dixie store pharmacies. Another principal distribution alliance is with Albertson's, which currently carries Ives' products in 182 stores in Texas and Oklahoma. It is anticipated that Albertson's will phase Ives' products into a majority of its 2,400 stores on a division by division basis, with full implementation on a national basis anticipated by the end of 1999. Albertson's is currently conducting a unique validation and testing program designed to verify the effectiveness of Ives' products and to gain insurance company endorsements. This testing program, which is progressing favorably, is expected to be completed by December 31, 1999. Maxxon is a development stage company with the exclusive worldwide license to develop, manufacture and market a proprietary safety syringe. Maxxon's simple design enables the needle to retract automatically after a single use. This syringe can be used and operated with one hand and is expected to have a major impact on the reduction of needlestick injuries in the United States andthroughout the world. For more information about Maxxon, contact Morgan-Phillips, Inc. at (800) 770-4856 or (918) 250-8028, or www.Morgan-Phillips.com. For more information about Ives Health Company, contact Keith Ives or Perry Ives at (918) 283-1226. For more information concerning Ives Common Stock, contact Jim Alexander at J. Alexander Securities (213) 687-8400. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, the ability of Maxxon, Inc. to accomplish its stated plan of business. Although Maxxon believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Maxxon or any other person that the objectives and plans of Maxxon will be achieved. Copyright (C) 1999 Business Wire. All rights reserved. -0- CONTACT: Morgan Phillips, Inc. 800/770-4856 or 918/250-8028 WEB PAGE: www.Morgan-Phillips.com businesswire.com GEOGRAPHY: OKLAHOMA INDUSTRY CODE: MEDICAL MANAGEMENT CHANGES Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. bcjt